XERS
Q3 2026 EPS Estimate
$0.02
Aug 6, 2026 · Reports before open
Revenue Estimate
$90M
FY2026E EPS$0.15
FY2027E EPS$0.36

Analyst Sentiment

Wall St. Consensus
Buy
10 analysts·Moderate coverage
73
Score
9 Buy (90%)1 Hold (10%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
990%
Hold
110%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$4.00
-54.6%
Consensus
$6.60
-25.0%
Bull
$18.00
+104.5%
12-Month Target Range10 analysts
$4.00$6.60$18.00
Current $8.80Consensus
Current Price
$8.80
Above Consensus
$2.20

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+22.50%
EPS+151.48%
FY2028
Rev+14.71%
EPS+61.55%
FY2029
Rev+15.05%
EPS+59.41%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$386M$473M$542M$624M$706M
Low$385M$454M$542M$608M$688M
High$388M$486M$543M$638M$722M
EBITDA Avg$-139M$-170M$-195M$-224M$-254M
Low$-139M$-175M$-195M$-230M$-260M
High$-138M$-163M$-195M$-219M$-248M
EBIT Avg$-162M$-198M$-228M$-262M$-296M
Low$-163M$-204M$-228M$-268M$-303M
High$-161M$-191M$-228M$-255M$-289M
Net Income Avg$20M$62M$105M$162M$194M
Low$15M$32M$64M$157M$188M
High$40M$88M$170M$167M$200M
EPS Avg$0.15$0.36$0.59$0.94$1.13
Low$0.08$0.19$0.37$0.91$1.09
High$0.23$0.51$0.98$0.97$1.16
Analysts (Rev / EPS)5 / 45 / 46 / 65 / 43 / 2
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$101M$111M$105M$114M$123M$135M$122M$128M
Low$100M$110M$104M$112M$121M$134M$120M$126M
High$103M$113M$107M$115M$125M$137M$123M$130M
EBITDA Avg$-36M$-40M$-38M$-41M$-44M$-49M$-44M$-46M
Low$-37M$-41M$-38M$-42M$-45M$-49M$-44M$-47M
High$-36M$-39M$-37M$-40M$-44M$-48M$-43M$-45M
EBIT Avg$-43M$-47M$-44M$-48M$-52M$-57M$-51M$-54M
Low$-43M$-47M$-45M$-48M$-52M$-58M$-52M$-55M
High$-42M$-46M$-44M$-47M$-51M$-56M$-50M$-53M
Net Income Avg$8M$12M$9M$13M$19M$26M$18M$18M
Low$5M$12M$9M$13M$18M$25M$17M$17M
High$13M$12M$9M$13M$19M$26M$18M$18M
EPS Avg$0.04$0.07$0.05$0.07$0.11$0.14$0.10$0.10
Low$0.03$0.06$0.05$0.07$0.10$0.14$0.10$0.10
High$0.07$0.07$0.05$0.07$0.11$0.15$0.10$0.10
Analysts (Rev / EPS)4 / 33 / 13 / 12 / 12 / 13 / 12 / 11 / 1

Earnings Surprises

Recent Analyst Actions

Dec 8, 2025Barclays
Xeris Biopharma initiated with an Overweight at Barclays
Target:$9.00
+28.8%from $6.99
Oct 29, 2025Oppenheimer
Xeris Biopharma price target raised to $18 from $8 at Oppenheimer
Target:$18.00
+80.5%from $9.97
Mar 7, 2025Piper Sandler
Xeris Biopharma price target raised to $4 from $3 at Piper Sandler
Target:$4.00
-5.7%from $4.24
Nov 11, 2024H.C. Wainwright
Xeris Pharmaceuticals (XERS) PT Raised to $6.60 at H.C. Wainwright
Target:$6.60
+103.4%from $3.25
Oct 23, 2024Oppenheimer
Oppenheimer Reiterates Outperform Rating on Xeris Pharmaceuticals (XERS)
Target:$5.00
+65.6%from $3.02
May 10, 2024Piper Sandler
Xeris Pharmaceuticals (XERS) PT Lowered to $3 at Piper Sandler
Target:$3.00
+62.4%from $1.85
Apr 28, 2022Craig-Hallum
Craig-Hallum Initiates Coverage On Xeris Biopharma Holdings with Buy Rating, Announces Price Target of $6.5
Target:$6.50
+179.0%from $2.33
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.